Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 5,051 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule 2 Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 30, 2026, 5:08 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

NCT04880278
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Nabilone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions

NCT00694317
View directory record Official record
Conditions
Short Term Treatment of Insomnia
Interventions
Zaleplon
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
View directory record Official record
Conditions
Age-related Macular Degeneration, Cataract
Interventions
Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
Dietary Supplement · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
4,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 30, 2026, 5:08 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps

NCT02285283
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Itraconazole, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 30, 2026, 5:08 PM EDT
Recruiting Phase 3 Interventional

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Placebo
Drug
Lead sponsor
Prilenia
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Acute Grape Seed Extract Supplementation on the Heart Rate Recovery in Young Individuals

NCT07137988
View directory record Official record
Conditions
Healthy Young Men
Interventions
600 mg grape seed extract, 600 mg Starch
Dietary Supplement
Lead sponsor
California Baptist University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

NCT02307461
View directory record Official record
Conditions
Healthy
Interventions
IPI-145 (duvelisib), IPI-145
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years to 50 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)

NCT05558696
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Bomedemstat
Drug
Lead sponsor
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Plantation, Florida • Skokie, Illinois • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 30, 2026, 5:08 PM EDT
Not listed Phase 2 Interventional

Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor

NCT02724527
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Cavosonstat, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 30, 2026, 5:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

NCT03490162
View directory record Official record
Conditions
Malaria
Interventions
DM1157, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Not applicable Interventional

Endoscopic Ultrasound vs Percutaneous Route for Liver Biopsy

NCT04003766
View directory record Official record
Conditions
Liver Biopsy
Interventions
biopsy
Diagnostic Test
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 30, 2026, 5:08 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)

NCT02033941
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Meganatural-Az Grapeseed Extract, Placebo
Drug
Lead sponsor
Hillel Grossman
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 5:08 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rapid Response of Stem Cells and Immune Cells for Efficacy

NCT07127705
View directory record Official record
Conditions
Stem Cell Surveillance
Interventions
Placebo, Chaga Mushroom, Ginseng extract, Olive extract, Potassium Hydrogen Glucarate
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of QVA149 in COPD Patients

NCT02487446
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
58
States / cities
Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03739203
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
58
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

NCT04902105
View directory record Official record
Conditions
Drug Interaction
Interventions
ecopipam HCL, Mefenamic acid, Divalproex Sodium ER
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 30, 2026, 5:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

NCT00880841
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine / Naloxone
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 30, 2026, 5:08 PM EDT
Terminated Phase 1 Interventional

Effects of Propranolol on Responses to Drug-Related Imagery Scripts

NCT00688805
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Propranolol, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 5:08 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

NCT04946383
View directory record Official record
Conditions
Aging
Interventions
Dasatinib plus Quercetin
Drug
Lead sponsor
TruDiagnostic
Industry
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Phase 4 Interventional Results available

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

NCT00359788
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Combivent (Ipratropium/Albuterol)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

NCT03005327
View directory record Official record
Conditions
WHIM Syndrome
Interventions
X4P-001
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 30, 2026, 5:08 PM EDT
Completed Not applicable Interventional Results available

Family-based Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity

NCT02060279
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Lifestyle intervention and carotenoid supplements, Lifestyle intervention and placebo
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
8 Years to 11 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 30, 2026, 5:08 PM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 5:08 PM EDT